Coronary Artery Restenosis
10
3
3
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (10)
Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study
Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
Disease Characteristics of IR-CAD: a Case-control Study
Resveratrol Excipient Paclitaxel Coated Balloon for Coronary Treatment
ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.
EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease
XIENCE V: SPIRIT WOMEN
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
XIENCE V: SPIRIT WOMEN Sub-study
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)